Marker Therapeutics 将来の成長

Future 基準チェック /26

Marker Therapeuticsの収益は年間38.9%で減少すると予測されていますが、年間収益は年間70.7%で増加すると予想されています。EPS は年間10.4%で減少すると予想されています。

主要情報

-38.9%

収益成長率

-10.4%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	70.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 Nov 2024

今後の成長に関する最新情報

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29

Marker Therapeutics EPS misses by $0.02

Nov 09

業績と収益の成長予測

NasdaqCM:MRKR - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2	-67	N/A	N/A	1
12/31/2025	4	-44	N/A	N/A	1
12/31/2024	5	-11	N/A	N/A	1
9/30/2024	5	-10	-9	-9	N/A
6/30/2024	4	-10	-11	-11	N/A
3/31/2024	3	-12	-14	-14	N/A
12/31/2023	3	-14	-16	-16	N/A
9/30/2023	3	-14	-20	-20	N/A
6/30/2023	4	-17	-27	-27	N/A
3/31/2023	4	-14	-18	-21	N/A
12/31/2022	4	-20	-27	-27	N/A
9/30/2022	4	-26	-26	-26	N/A
6/30/2022	3	-33	-27	-25	N/A
3/31/2022	2	-43	-36	-31	N/A
12/31/2021	1	-42	-30	-27	N/A
9/30/2021	N/A	-41	-35	-28	N/A
6/30/2021	N/A	-36	-34	-27	N/A
3/31/2021	0	-31	-35	-24	N/A
12/31/2020	0	-29	-29	-20	N/A
9/30/2020	1	-25	-24	-19	N/A
6/30/2020	1	-23	-23	-19	N/A
3/31/2020	0	-23	-19	-19	N/A
12/31/2019	0	-21	-19	-18	N/A
9/30/2019	N/A	-152	-20	-20	N/A
6/30/2019	N/A	-151	-18	-18	N/A
3/31/2019	0	-150	-16	-16	N/A
12/31/2018	0	-148	-15	-14	N/A
9/30/2018	0	-15	-11	-11	N/A
6/30/2018	0	-15	N/A	-9	N/A
3/31/2018	0	-12	N/A	-9	N/A
12/31/2017	0	-11	N/A	-8	N/A
9/30/2017	0	-10	N/A	-8	N/A
6/30/2017	N/A	-8	N/A	-8	N/A
3/31/2017	N/A	0	N/A	-8	N/A
12/31/2016	N/A	-2	N/A	-7	N/A
9/30/2016	N/A	-3	N/A	-6	N/A
6/30/2016	N/A	28	N/A	-5	N/A
3/31/2016	N/A	-38	N/A	-4	N/A
12/31/2015	N/A	-34	N/A	-4	N/A
9/30/2015	N/A	-33	N/A	-4	N/A
6/30/2015	N/A	-63	N/A	-3	N/A
3/31/2015	N/A	-2	N/A	-3	N/A
12/31/2014	N/A	-31	N/A	-2	N/A
9/30/2014	N/A	-34	N/A	-1	N/A
6/30/2014	N/A	-33	N/A	-1	N/A
3/31/2014	N/A	-35	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MRKR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MRKR今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MRKR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MRKRの収益 ( 70.7% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: MRKRの収益 ( 70.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MRKRの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Marker Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Consensus revenue estimates fall by 41%

Price target decreased to US$3.63

Price target decreased to US$5.63

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.47 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

New major risk - Share price stability

Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study

Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse

Second quarter 2023 earnings released: US$0.47 loss per share (vs US$1.11 loss in 2Q 2022)

Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen (Multitaa)-Specific T Cell Product Candidate, Mt-401

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration

Marker Therapeutics, Inc. Reports Pre-Clinical Data of Its MT-601 multiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Marker Therapeutics Announces U.S. Food and Drug Administration Clearance of IND for MT-601, Its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics Wins $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 Artemis Trial of Mt-401 in Post-Transplant AML

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Nasdaq Grants an Additional 180-Calendar Day Compliance Period to Marker Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 41%

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics, Inc. Announces FDA Clearance of IND for Mt-601, the Six-Antigen Targeted T Cell Therapy for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Price target decreased to US$3.63

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Full year 2021 earnings: EPS misses analyst expectations

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Clinical Program Updates and Pipeline Expansion

Price target decreased to US$5.63

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from Russell 3000E Value Index

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Earnings beat expectations, revenue disappoints

Marker Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Trial of Mt-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

New 90-day high: US$3.19

Marker shares rise as it completes construction of its cGMP manufacturing facility

New 90-day high: US$1.79

Marker Therapeutics, Inc. Announces U.S. Food and Drug Administration Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.75

Earnings beat expectations

Marker Therapeutics EPS misses by $0.02

New 90-day low: US$1.43

New 90-day low: US$1.50

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from S&P Global BMI Index

New 90-day low - US$1.65

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘